3-methyl-4-phenylbenzonitrile | 5002-17-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3-methyl-4-phenylbenzonitrile
• 英文别名: 4-cyano-2-methylbiphenyl
• CAS: 5002-17-5
• 化学式: C₁₄H₁₁N
• 分子量: 193.248
• InChiKey: HNMVDGFMLKHLPJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  15
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  23.8
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  4-溴-3-甲基苯甲腈 、 苯硼酸 生成 3-methyl-4-phenylbenzonitrile
  参考文献：
  名称：

  Purinenucleoside derivative modified in 8-position and medical use thereof

  摘要：

  本发明提供了一种8-修饰嘌呤核苷衍生物，该衍生物对于与血浆尿酸水平异常相关的疾病非常有用。式(I)所表示的8-修饰嘌呤核苷衍生物，其前药或其药学上可接受的盐，或其水合物或溶剂化物，对于痛风、高尿酸血症、尿路结石、高尿酸性肾病等的预防或治疗非常有用。在该式中，n为1或2；RA是氢原子或羟基；R1是氢原子、羟基、硫醇基、氨基或氯原子；环J表示可选取的2-萘基团，或由以下通式(II)所表示的团，其中Y表示单键或连接基团；环Z表示可选取的芳基团或杂环芳基团等；R2至R4、P1和Q表示卤素原子、氰基或类似物。

  公开号：

  US20070179115A1

文献信息

• Purinenucleoside derivative modified in 8-position and medical use thereof
  申请人：Tatani Kazuya

  公开号：US20070179115A1

  公开（公告）日：2007-08-02

  The present invention provides an 8-modified purinenucleoside derivative which is useful for diseases associated with an abnormality of plasma uric acid level. An 8-modified purinenucleoside derivative represented by the following formula (I), a prodrug thereof or a pharmaceutically acceptable salt thereof, or a hydrate or solvate thereof, is useful for the prevention or treatment of gout, hyperuricemia, urinary lithiasis, hyperuricemic nephropathy or the like. In the formula, n is 1 or 2; R A is a hydrogen atom or a hydroxyl group; R 1 is a hydrogen atom, a hydroxyl group, a thiol group, an amino group or a chlorine atom; ring J represents an optionally substituted 2-naphthyl group, or a group represented by the following general formula (II) wherein Y represents a single bond or a connecting group; ring Z represents an optionally substituted aryl group or heteroaryl group or the like; and R 2 to R 4 , P 1 and Q represents a halogen atom, a cyano group or the like.

  本发明提供了一种用于与血浆尿酸水平异常相关疾病的8-修饰嘌呤核苷衍生物。以下式（I）所代表的一种8-修饰嘌呤核苷衍生物、其前药或药用盐、或其水合物或溶剂化合物，对于痛风、高尿酸血症、尿路结石、高尿酸性肾病等的预防或治疗具有用处。在该式中，n为1或2；RA是氢原子或羟基；R1是氢原子、羟基、硫醇基、氨基或氯原子；环J代表可选地取代的2-萘基，或由以下一般式（II）所代表的基团，其中Y代表单键或连接基团；环Z代表可选地取代的芳基或杂环芳基等；而R2至R4、P1和Q代表卤素原子、氰基或类似物。
• [EN] 2-(2-AZABICYCLO[3.1.0]HEXAN-1-YL)-1H-BENZIMIDAZOLE DERIVATIVES<br/>[FR] DÉRIVÉS DE 2-(2-AZABICYCLO [3.1.0] HEXAN-1-YL)-1H-BENZIMIDAZOLE
  申请人：IDORSIA PHARMACEUTICALS LTD

  公开号：WO2020007964A1

  公开（公告）日：2020-01-09

  The present invention relates to compounds of the Formula (I) wherein Ar1, R1, and (R5)n are as described in the description, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of Formula (I), and especially to their use as orexin receptor antagonists.

  本发明涉及式（I）的化合物，其中Ar1，R1和（R5）n如描述中所述，以及它们的制备，其药学上可接受的盐，以及它们作为药物的用途，包括含有一种或多种式（I）化合物的药物组合物，特别是它们作为促进睡眠的奥莱欣受体拮抗剂的用途。
• CONDENSED CYCLIC COMPOUND, COMPOSITION INCLUDING THE CONDENSED CYCLIC COMPOUND, AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING CONDENSED CYCLIC COMPOUND
  申请人：Samsung Electronics Co., Ltd.

  公开号：US20190229276A1

  公开（公告）日：2019-07-25

  A condensed cyclic compound represented by Formula 1: wherein in Formula 1, Ar 11 , Ar 12 , R 11 , R 12 , R 13 , and R 14 are the same as described in the specification.

  由式1表示的一种紧凑的环状化合物：其中在式1中，Ar11、Ar12、R11、R12、R13和R14与规范中描述的相同。
• PROCESS FOR PREPARING 4-SUBSTITUTED 2-ALKYLBIPHENYLS AND 2-ALKOXYLBIPHENYLS
  申请人：Clariant GmbH

  公开号：US20020115880A1

  公开（公告）日：2002-08-22

  A process for preparing 4-substituted 2-alkylbiphenyls and 2-alkoxybiphenyls of the formula (I), 1 by reaction of phenylboronic acids of the formula (II) with 4-bromo- or 4-iodo-alkyl- or -alkoxy-anilines or -anilides of the formula (III) to form compounds of the formula (IV), 2 if appropriate subsequent deacylation to form (V) and subsequent diazotization to form compounds of the formula (VI) and reaction with a nucleophile X, a Cu salt by the Sandmeyer reaction or a reducing agent to give 4-substituted 2-alkylbiphenyls and 2-alkoxybiphenyls of the formula (I). 3

  一种制备式(I)的4-取代2-烷基联苯和2-烷氧基联苯的方法，通过将式(II)的苯基硼酸与式(III)的4-溴或4-碘烷基或烷氧基苯胺或苯酰胺反应，形成化合物式(IV)，如有必要进行脱酰化反应形成(V)，然后进行重氮化反应形成化合物式(VI)，并与亲核试剂X、Sandmeyer反应的Cu盐或还原剂反应，以得到式(I)的4-取代2-烷基联苯和2-烷氧基联苯。
• PURINE NUCLEOSIDE DERIVATIVE MODIFIED IN 8-POSITION AND MEDICAL USE THEREOF
  申请人：Tatani Kazuya

  公开号：US20100249054A9

  公开（公告）日：2010-09-30

  The present invention provides an 8-modified purinenucleoside derivative which is useful for diseases associated with an abnormality of plasma uric acid level. An 8-modified purinenucleoside derivative represented by the following formula (I), a prodrug thereof or a pharmaceutically acceptable salt thereof, or a hydrate or solvate thereof, is useful for the prevention or treatment of gout, hyperuricemia, urinary lithiasis, hyperuricemic nephropathy or the like. In the formula, n is 1 or 2; R A is a hydrogen atom or a hydroxyl group; R 1 is a hydrogen atom, a hydroxyl group, a thiol group, an amino group or a chlorine atom; ring J represents an optionally substituted 2-naphthyl group, or a group represented by the following general formula (II) wherein Y represents a single bond or a connecting group; ring Z represents an optionally substituted aryl group or heteroaryl group or the like; and R 2 to R 4 , P 1 and Q represents a halogen atom, a cyano group or the like.

  本发明提供了一种8-修饰嘌呤核苷衍生物，用于与血浆尿酸水平异常相关的疾病。公式（I）所表示的8-修饰嘌呤核苷衍生物，其前体药物或其药学上可接受的盐，或其水合物或溶剂化物，可用于痛风、高尿酸血症、泌尿系结石、高尿酸性肾病等的预防或治疗。在公式中，n为1或2；RA是氢原子或羟基；R1是氢原子、羟基、硫醇基、氨基或氯原子；环J表示可选取的2-萘基团，或由以下通式（II）所表示的基团，其中Y表示单键或连接基团；环Z表示可选取的芳基团或杂环芳基团等；R2到R4、P1和Q表示卤素原子、氰基或类似物。